1 Waist circumference thresholds predicting incident dysglycemia and type 2

2 diabetes in Black African men and women

- 3
- 4 **Running title:** Waist thresholds for type 2 diabetes in Africa
- 5
- 6 Julia H. Goedecke^{1,2}, Kim Nguyen¹, Clement Kufe², Maphoko Masemola², Tinashe
- 7 Chikowore², Amy E. Mendham^{2,3}, Shane A. Norris², Nigel J. Crowther⁴, Fredrik Karpe⁵,
- 8 Tommy Olsson⁶, Andre Pascal Kengne¹, Lisa K Micklesfield²
- 9
- ¹Non-Communicable Diseases Research Unit, South African Medical Research
- 11 Council, Cape Town, South Africa
- ¹² ²South African Medical Research Council/WITS Developmental Pathways for Health
- 13 Research Unit (DPHRU), Department of Paediatrics, Faculty of Health
- 14 Sciences, University of the Witwatersrand, Johannesburg, South Africa
- ¹⁵³Health through Physical Activity, Lifestyle and Sport Research Centre (HPALS),
- 16 FIMS International Collaborating Centre of Sports Medicine, Division of Physiological
- 17 Sciences, Department of Human Biology, Faculty of Health Sciences, University of
- 18 Cape Town
- ⁴Department of Chemical Pathology, National Health Laboratory Service and School
- 20 of Pathology, Faculty of Health Sciences, University of the Witwatersrand,
- 21 Johannesburg, South Africa
- ⁵Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM), Nuffield
- 23 Department of Clinical Medicine, University of Oxford, Oxford, U.K.
- ⁶Department of Public Health and Clinical Medicine, Medicine, Umeå University, Umeå,
- 25 Sweden

26

27 Corresponding Author:

- 28 Julia H. Goedecke
- 29 Non-Communicable Diseases Research Unit, South African Medical Research
- 30 Council, Francie van Zijl Drive, Parow Valley, 7505, Cape Town, South Africa
- 31 Tel: +27-219380862
- 32 Email: Julia.goedecke@mrc.ac.za
- 33
- 34 Abstract count: 249
- 35 Word count: 3787
- 36 Tables/figures: 4
- 37

38 KEYWORDS

39 Sub-Saharan African cohort, risk stratification, obesity, metabolic syndrome,

41 **ABSTRACT**

Objective: To determine the waist circumference (WC) thresholds for the prediction
of incident dysglycemia and type 2 diabetes in Black South African (SA) men and
women and compare these to advocated International Diabetes Federation (IDF)
Europid thresholds.

46 **Research design and methods**: In this prospective study, Black SA men (n=502) 47 and women (n=527) from the Middle Aged Sowetan Cohort (MASC) study who had 48 normal or impaired fasting glucose at baseline (2011-2015) were followed up through 49 2017-2018. Baseline measurements included anthropometry, blood pressure and 50 fasting glucose, HDL-cholesterol and triglyceride concentrations. At follow-up, glucose 51 tolerance was assessed using an oral glucose tolerance test. The Youden index was 52 used to determine the optimal threshold of WC to predict incident dysglycemia and 53 type 2 diabetes.

Results: In men, the optimal WC threshold was 96.8 cm for both dysglycemia and type 2 diabetes (sensitivity 56 and 70%, specificity 74 and 70%, respectively), which performed similarly to the IDF threshold of 94 cm. In women, the optimal WC threshold for incident dysglycemia was 91.8 cm (sensitivity 86%, specificity 37%) and for type 2 diabetes was 95.8 cm (sensitivity 85%, specificity 45%). In comparison, the IDF threshold of 80 cm in women had higher sensitivity (97 and 100%), but lower specificity (12 and 11%) to predict incident dysglycemia and type 2 diabetes, respectively.

Conclusions: In this first prospective study of incident type 2 diabetes in Africa, we
show that African-specific WC thresholds perform better than the IDF WC thresholds
to predict incident dysglycemia and type 2 diabetes.

64

65 **INTRODUCTION**

66 The global prevalence of type 2 diabetes is increasing, with sub-Saharan Africa (SSA) 67 having the highest projected relative rates of increase (1). The burden of type 2 68 diabetes in SSA is reflected by the high estimated type 2 diabetes-associated deaths 69 (~312,000 deaths in 2017), with 73% of these being in people under the age of 60 70 years, a higher proportion than any other region in the world (1). Within SSA, South 71 Africa (SA) has the highest number of people with type 2 diabetes (1), and type 2 72 diabetes was the second leading cause of death in SA in 2016 (5.5% of deaths), and 73 the highest amongst women (7.2% of deaths) (2). Notably, SSA has the highest 74 proportion (59.7%) of people with undiagnosed type 2 diabetes (1). Accordingly, risk 75 stratification that is accessible and cost effective is essential for the early detection of 76 type 2 diabetes to prevent or delay the progression of the disease.

77

78 Obesity, in particular central obesity, are important risk factors for type 2 diabetes (3; 79 4). Although imaging techniques are more accurate measures of total and central 80 adiposity, they are not practical or affordable for routine practice and population-based 81 risk stratification. Accordingly, anthropometric measures are used as surrogate 82 markers for risk stratification for type 2 diabetes. Body mass index (BMI) is the most 83 commonly used proxy of total adiposity, while waist circumference (WC), waist-to-hip 84 ratio (WHR) and waist-to-height ratio (WHtR) are used as proxy measures of central 85 adiposity (5). Waist circumference requires only a single measure, is not reliant on a 86 ratio that is difficult to interpret and is the most accepted marker of central adiposity 87 and disease risk (4; 6).

88

89 Waist circumference represents the sum of abdominal visceral (VAT) and 90 subcutaneous adipose tissue (SAT), with VAT being the most significant determinant 91 of type 2 diabetes (7; 8). However, we and others have shown that for the same level 92 of WC, Black Africans have less VAT than their white European counterparts (9-11). 93 Accordingly, the WC threshold used for defining risk for type 2 diabetes may differ in 94 Black Africans. Indeed, both the World Health Organization (WHO) and the 95 International Diabetes Federation (IDF) acknowledge that optimal thresholds for 96 abdominal obesity vary across different ethnicities and population groups (6; 12). 97 Although, several studies in SSA have been undertaken to identify WC thresholds for 98 risk, these have all been cross-sectional and relied on metabolic syndrome (MetS) 99 (excluding WC) as the outcome (13-16). As there is no consensus on an appropriate 100 WC threshold for Black Africans, the IDF has recommended the use of Europid 101 thresholds (\geq 80 cm in women and \geq 94 cm in men) for SSA (6). Prospective studies 102 are therefore required to identify the optimal WC thresholds that identifies incident type 103 2 diabetes in Black African men and women.

104

105 While WC is regarded as a useful primary screening tool for type 2 diabetes, it is also 106 a key feature of the MetS, which is also typically used in risk prediction for type 2 107 diabetes and cardiovascular diseases (6). The MetS is a cluster of risk factors that 108 occur together more often than by chance alone, and in addition to WC, include 109 elevated blood pressure, fasting glucose and triglycerides, and low fasting HDL-110 cholesterol concentrations (6). However, it is not clear whether including these 111 additional MetS risk factors improves the discriminatory ability to predict type 2 112 diabetes in African men and women when compared to WC alone.

113

Therefore, the aim of the study was to determine the WC thresholds for the prediction of incident dysglycemia (prediabetes and type 2 diabetes) and type 2 diabetes in Black SA men and women, and to compare these to advocated Europid thresholds, as defined by the IDF. A secondary aim was to determine if the derived WC thresholds for the prediction of incident dysglycemia and type 2 diabetes performed similarly to the MetS in Black SA men and women.

- 120
- 121

122 METHODS

123 Design, study population and setting

124 Baseline data collection was part of the African WITS-INDEPTH Partnerships for 125 Genomic Research (AWI-Gen) Collaborative Centre which is a Human Heredity and 126 Health in Africa (H3A) Consortium study (17; 18), and included 1027 men and 1004 127 women from which the Middle-aged Soweto Cohort (MASC) was randomly selected 128 (n=1112). The MASC cohort is a longitudinal study of Black SA men and women 129 residing in Soweto, SA on whom baseline data was collected between 2011 and 2015, 130 and again between January 2017 and August 2018 (Figure 1). Data in this study was 131 collected from a sample of 1029 participants (502 men and 527 women) who were 132 representative of the AWI-Gen sample and did not differ in terms of age, sex, 133 sociodemographic or lifestyle factors from the main cohort (data not shown). Only 134 participants with normal glucose tolerance or impaired fasting glucose, and 135 anthropometric measures at baseline, as well as measures of glycaemia from an oral 136 glucose tolerance test at follow-up, were included in this analysis (Figure 1). Complete 137 data was available for 890 participants (452 men and 438 women).

138

The study was conducted in accordance with the Declaration of Helsinki and was approved by the Human Research Ethics Committee (HREC) (Medical) of the University of the Witwatersrand (Clearance Certificate No. M160604 and M160975). Prior to inclusion in the study, all the procedures and possible risks were explained to the participants prior to providing signed consent.

144

145 Socio-demographic and health questionnaires

The same interviewer-administered questionnaire was completed at both time points and included age, current employment (employed/not employed), and highest educational level attained (no formal schooling/elementary school, secondary school, tertiary education). In addition, participants were asked to bring all other current medications, including diabetes medications, to the testing facility for recording and verification. Participants were classified as current smokers/non-smokers and current alcohol consumers/non-consumers.

153

154 Anthropometry and blood pressure

155 Weight was measured to the nearest 0.1 kg using a TANITA digital scale (model: TBF-156 410, TANITA Corporation, US). Height was measured to the nearest 0.1 cm using a 157 wall-mounted stadiometer (Holtain, Crymych, UK). Waist circumference and hip 158 circumference were measured to the nearest 0.1 cm with a non-stretchable tape. 159 Waist circumference was measured in the mid-axillary line at the midpoint between 160 the lower margin of the last palpable rib and the top of the iliac crest at the end of 161 normal expiration, and hip circumference was measured as the greatest protrusion of 162 the buttocks (12). Waist-to-hip ratio (WHR), waist-height ratio (WHtR) and body mass 163 index (BMI) were calculated. Participants were categorized according to the WHO

164 criteria: underweight (BMI <18.5 kg/m²), normal weight (BMI: 18.5-24.9 kg/m²), 165 overweight (25-29.9 kg/m²) and obese (BMI \ge 30 kg/m²).

166

Systolic and diastolic blood pressure were measured on the left arm using a digital blood pressure monitor (Omron M6, Kyoto, Japan) and appropriate cuffs. After the participant had been seated for at least five minutes, three blood pressure readings were taken at two-minute intervals. For each participant, the average of the second and third readings were used in the analyses.

172

173 Blood sampling and biochemistry

174 At both baseline and follow-up, blood samples were drawn after an overnight fast (10-175 12 hours) for the measurement of plasma glucose and serum lipid (total cholesterol, 176 HDL-cholesterol, LDL-cholesterol and triglyceride) concentrations. In the follow-up 177 sample only, participants then completed a standard 2-hour oral glucose tolerance 178 test (OGTT). After ingestion of 75 g of anhydrous glucose in 250 ml water within 5 179 minutes, blood samples were drawn at 30 min intervals for 2 hours for the subsequent 180 determination of plasma glucose concentrations. Participants with known diabetes 181 and/or those with fasting blood glucose ≥11.1 mmol/l (ACCU-CHEK[®] point-of-care 182 glucose analyzer, MedNet GmbH, Munster, Germany) did not complete the OGTT.

183

Serum lipid concentrations at baseline and plasma glucose concentrations at baseline
 and follow-up were measured on the Randox RX Daytona Chemistry Analyzer using
 enzymatic methods (Randox Laboratories Ltd., Crumlin, Northern Ireland). The LDL cholesterol concentrations were calculated using the Friedewald equation (19).

188

189 Glucose tolerance and metabolic syndrome (MetS) classification

190 Glucose tolerance was defined based on the WHO criteria (20). At baseline, only 191 fasting glucose samples were available, and hence the participants were classified as 192 having normal glucose tolerance (NGT) if fasting glucose was <6.1 mmol/L; impaired 193 fasting glucose (IFG) if fasting glucose was 6.1-6.9 mmol/l; or type 2 diabetes if fasting 194 glucose was ≥7 mmol/l and/or taking type 2 diabetes medications. Only those with 195 NGT or IFG at baseline were included in this study. At follow-up, glucose tolerance was defined based on both fasting and 2 hour OGTT results as follows: NGT if fasting 196 197 glucose was <6.1 mmol/l and 2-hour post glucose load was <7.8 mmol/L; IFG (as 198 defined above); impaired glucose tolerance (IGT) if 2-hour post glucose load was 7.8-199 11.0 mmol/L; and type 2 diabetes if fasting glucose was >7.0 mmol/L and/or 2-hour 200 post glucose load ≥11.1 mmol/L. Participants who were taking diabetes medications 201 were classified with type 2 diabetes. At follow-up dysqlycemia, which encompasses 202 both prediabetes and diabetes, was defined as IFG and/or IGT and/or type 2 diabetes. 203

The presence of the MetS was based on the 2009 harmonized criteria (6). Participants with three or more of the following components were classified as having the MetS: i) elevated waist circumference (\geq 94 cm in men or \geq 80 cm in women); ii) elevated fasting triglycerides (\geq 1.7 mmol/L); iii) reduced fasting HDL cholesterol (<1.0 mmol/L in men or <1.3 mmol/L in women); iv) elevated blood pressure (\geq 130 mmHg for systolic and/or \geq 85 mmHg for diastolic and/or using blood pressure medication); v) elevated fasting glucose (\geq 5.6 mmol/L and/or using diabetes medication).

211

212 Statistics

213 Data analysis was conducted in STATA SE Version 15 (StataCorp, College Station, 214 Tx, USA). Normality of the data was assessed using Shapiro Wilks test. As all the 215 descriptive variables were skewed, the continuous variables are presented as median (25-75th percentiles) and the categorical variables are presented as frequencies and 216 217 percentages. Wilcoxon-Mann-Whitney tests and Chi-square tests were used to 218 compare continuous and categorical variables between men and women, respectively. 219 Receiver operating characteristic (ROC) area-under-the-curves (AUC) were used to 220 assess and compare the ability of the baseline WC and other anthropometric 221 measures to predict incident dysglycemia (prediabetes or type 2 diabetes) and type 2 222 diabetes at follow-up. For the prediction of incident dysglycemia, only those with NGT 223 at baseline were included in the analysis, whereas for the prediction of incident type 2 224 diabetes, those with NGT and IFG at baseline were included in the analysis. Optimal 225 WC thresholds to predict incident dysglycemia and type 2 diabetes were determined 226 using Youden's index in men and women separately (21). The prognostic performance 227 of the WC thresholds derived in this longitudinal study were assessed alongside the 228 IDF-defined threshold, as well as WC thresholds defined in other South African and 229 African cross-sectional studies that have been used to predict the presence of at least 230 two components of the MetS, excluding WC (22). These studies were used as 231 comparators as, to our knowledge, there are no other studies that have previously 232 defined WC thresholds for predicting incident type 2 diabetes in Africa. Finally, we 233 determined whether including additional MetS risk factors together with the derived 234 WC threshold improved the prediction of incident dysglycemia and type 2 diabetes 235 compared to the derived WC thresholds alone.

236 **RESULTS**

237 Participant characteristics

238 At baseline, the sample were middle-aged (~50 years) with men being slightly older 239 than women (Table 1). More men were employed (65.0% vs. 53.0%, p<0.001) and 240 had completed secondary (75.0 vs. 16.9%) and tertiary education (16.4% vs. 0%), 241 compared to women (both p < 0.001). In addition, more men than women currently 242 smoked any form of tobacco (52.2% vs. 5.3%, p<0.001). In contrast, women had 243 significantly higher BMI and a greater proportion of women compared to men were 244 classified with overweight or obesity (88.6% vs. 47.4%, p<0.001, Table 1). Accordingly, 245 WC and WHtR were higher, but WHR was lower in women compared to men (Table 246 1). Fasting glucose concentrations were higher in men compared to women, but 247 women had higher triglyceride, total- and LDL-cholesterol concentrations compared to 248 men, while HDL-cholesterol concentrations did not differ (Table 1). Similarly, both 249 systolic and diastolic blood pressure did not differ by sex. In terms of the sex 250 differences in MetS criteria, a greater proportion of women had elevated WC, while a 251 greater proportion of men had elevated fasting glucose and reduced HDL-cholesterol 252 concentrations; however, the prevalence of MetS did not differ significantly between 253 men and women.

254

The median (25-75th percentile) follow-up times were 3.1 (2.9-3.5) years in men and 4.8 (4.0-5.5) years in women. Of the 430 men and 421 women with NGT at baseline, 73 men and 101 women developed dysglycemia at follow-up, resulting in a cumulative incidence (95% confidence incidence (CI)) of 17.0 (13.4-28.1)% in men and 24.0 (19.9-41.1)% in women. Of the 452 men and 438 women with NGT or IFG at baseline, 20 men and 47 women developed type 2 diabetes at follow-up, resulting in a lower

261 cumulative incidence of type 2 diabetes (95% CI) in men (4.4 (2.5-5.9)%) compared
262 to women (10.7 (7.8-16.8)%).

263

264 Comparative abilities of anthropometric measures to predict incident dysglycemia and

265 type 2 diabetes

When comparing the discriminatory power of the anthropometric measures to predict incident dysglycemia and type 2 diabetes in men and women (Supplementary Table S1), we showed that there were no significant differences between any of the AUC's, except where WHtR performed better than BMI in predicting dysglycemia in men (p=0.017). As WC is a single simple measure that is most commonly used for risk prediction (6) and recommended for clinical practice (4), we chose to use this measure in all subsequent analyses.

273

274 Performance of different WC thresholds to predict incident dysglycemia and type 2
275 diabetes

276 The ROC analyses for WC to predict incident dysplycemia and type 2 diabetes in men 277 and women are presented in Figure 2. Waist circumference showed acceptable 278 discrimination to predict dysglycemia and type 2 diabetes in men and women, with the 279 AUCs being higher in men than women (Figure 2). Based on the Youden's index, the 280 optimal WC thresholds to predict incident dysglycemia in men and women were 96.8 281 cm and 91.8 cm, respectively (Table 2). In men, this threshold was similar to the IDF 282 threshold of 94 cm, and accordingly had similar sensitivity, specificity, and positive and 283 negative predictive values. However, the threshold of 96.8 cm was higher than those 284 derived from cross-sectional studies of other African populations to detect MetS (84-285 90 cm), with a resultant lower sensitivity, but higher specificity.

286

In women, the threshold of 91.8 cm to predict incident dysglycemia was higher than the IDF recommended threshold of 80 cm but was similar to most thresholds from other African studies to detect MetS (Table 2). Although the sensitivity was lower than the IDF threshold (0.86 vs. 0.97), the specificity (0.37 vs. 0.12) was higher using the derived threshold of 91.8 cm.

292

293 The optimal WC threshold to predict incident type 2 diabetes in men (Table 3) was the 294 same as that for dysglycemia (96.8 cm) and consequently all the performance 295 variables are the same as those reported for dysglycemia in Table 2. In contrast, the 296 optimal WC threshold to predict incident type 2 diabetes in women was 95.8 cm (Table 297 3), which is similar to the threshold for dysglycemia and type 2 diabetes in men, but 298 higher than the threshold for dysglycemia (91.8 cm), and the IDF cut point (80 cm) and 299 most other thresholds derived to detect MetS in African women (81-94 cm). Although 300 the sensitivity of the optimal threshold of 95.8 cm was lower than IDF (0.85 vs. 1.00) 301 and other African studies (0.87-1.00), the specificity was higher (0.45 vs. 0.11 and 302 0.12-0.40.

303

Comparative ability of derived WC thresholds vs. MetS to predict incident dysglycemia
 and type 2 diabetes

We then determined whether including additional MetS risk factors together with the derived WC thresholds improved the prediction of incident dysglycemia and type 2 diabetes compared to the derived WC thresholds alone. In Tables 2 and 3, we showed that the cut-point to predict incident dysglycemia and T2D in men, and T2D in women were similar (~96 cm). Other African studies that have examined cut-points to detect

311 MetS have also suggested similar cut-points for men and women (13; 15; 16). Thus, 312 we used the WC cut-point of 96 cm in both men and women as the WC component of 313 MetS and compared this to the WC cut-points alone, to predict incident dysglycemia 314 and T2D in men and women (Tables 2 and 3). Despite including additional risk factors, 315 MetS had lower sensitivity, but similar specificity compared to the optimal WC 316 threshold of 96.8 cm to predict incident dysglycemia and type 2 diabetes in men 317 (Tables 2 and 3). In contrast, the sensitivity of MetS using a WC threshold of 96cm to 318 predict both incident dysglycemia and type 2 diabetes in women was lower than the 319 derived thresholds alone, while the specificity was higher (Tables 2 and 3).

320

321

322 DISCUSSION

This is the first prospective study to examine WC thresholds to predict incident dysglycemia and type 2 diabetes in an African population and showed that the optimal thresholds differed to those in European populations. The optimal thresholds to predict incident dysglycemia and type 2 diabetes in Black SA men were 96.8 cm for both outcomes and in women 91.8 and 95.8 cm, respectively. Importantly, these Africanspecific WC thresholds had higher specificity than the IDF Europid thresholds.

329

The WC thresholds to predict incident dysglycemia and type 2 diabetes in women were higher than the IDF threshold of 80 cm. This is consistent with the findings of several cross-sectional studies in SA that detected MetS, defined as at least two components of the MetS excluding WC, and reported optimal thresholds of 90-94 cm (13; 14; 16; 23). We showed that in women the thresholds of 91.8 and 95.8 cm had lower sensitivity and higher specificity than the IDF threshold to predict incident

dysglycemia and type 2 diabetes, respectively. The specificity of the IDF threshold was as low as 0.11, suggesting 89% of Black SA women who will remain free of dysglycemia or type 2 diabetes over time may be incorrectly classified among those who will go on to develop the conditions if this threshold was used alone as a risk screening tool.

341

342 Nonetheless, the devised African-specific threshold still had low specificity (0.37 and 343 0.45) for incident dysglycemia and type 2 diabetes in Black SA women. This was also 344 lower than that reported in Black SA men using the derived threshold of 96.8 cm 345 (specificity ~0.70). The poor discriminatory ability of the WC thresholds to predict 346 incident dysglycaemia and type 2 diabetes in women may be due to their high levels 347 of obesity (66.7% vs. 20.9%) and central obesity (90% WC >80 cm vs. 37.6% WC >94 348 cm) compared to the men in this sample. However, this is representative of men and 349 women of this age group in SA (24). Further, these discrepant findings may be 350 explained by the stronger association between total and central adiposity and type 2 351 diabetes risk in Black SA men compared to Black SA women (Kufe et al, in review). 352 Waist circumference incorporates both VAT and SAT; and it has been shown in Black 353 South Africans and African-born Black people living in America that for the same WC, 354 women have less VAT and more abdominal SAT than men (25) (Kufe et al., in review). 355 Higher SAT for every level of VAT explained the higher WC cut point required for 356 predicting insulin resistance in African-born black women living in America compared 357 to their male counterparts (96 cm vs. 91 cm) (25). Further, a prospective study in Black 358 SA women showed that only VAT, but not SAT, predicted the development of T2D (7). 359 Accordingly, high levels of SAT in Black SA women may mask the association with 360 VAT and lead to poor discriminatory power of WC to predict incident type 2 diabetes.

361

Previous studies from SSA have suggested that the WC of risk should be similar for African men and women (13; 15; 16). The findings from this study support this recommendation. Indeed, a WC of 96.8 cm predicted both incident dysglycemia and type 2 diabetes in men, whilst a very similar WC of 95.8 cm predicted incident type 2 diabetes in women. However, larger longitudinal studies are required to confirm our findings for the SA population. We do agree that WC thresholds are dependent on the underlying obesity prevalence and should be region specific (15).

369

370 Another important finding of this study was that when including additional MetS risk 371 factors together with the derived WC threshold to predict incident dysglycemia and 372 type 2 diabetes in men, the predictive accuracy did not change. In contrast, in women, 373 the inclusion of the additional MetS risk factors resulted in a decrease in sensitivity 374 (0.85-0.86 to 0.38-0.49), but an increase in specificity (0.37-0.45 to 0.80-0.76). In both 375 men and women, the most common feature of MetS were reduced HDL-cholesterol 376 and elevated blood pressure. In African populations, reduced HDL-cholesterol levels 377 are not necessarily a marker of cardiometabolic risk, and the WHO sex-based cut-offs 378 are inappropriate (26-28); while blood pressure is a risk factor for cardiovascular 379 disease rather than type 2 diabetes. Further, it has been previously shown that MetS 380 and its components, in particular triglyceride and HDL-cholesterol levels, are not 381 associated with insulin resistance in Black African women (29-31) and that MetS may 382 not be a good indicator of cardiometabolic risk in Black African populations (32-34). 383 The time and cost associated with these additional measures is unlikely to offset the 384 reduction in false positives associated with WC measures alone in Black SA women. 385 Concomitantly, this highlights the need for future studies to establish accessible and

cost-effective risk biomarkers that have high sensitivity and specificity for the early
detection of type 2 diabetes in SSA.

388

389 The major strengths of this study are the prospective design and the diagnosis of 390 incident dysglycemia and type 2 diabetes using an OGTT. To date, all studies that 391 have explored thresholds for WC have been cross-sectional and were designed for 392 identifying the optimal WC cut point for detecting MetS (13; 14; 16; 23). We used an 393 OGTT to diagnose type 2 diabetes at follow-up, which is considered the gold standard, 394 particularly in African populations where fasting glucose and HbA1c may perform sub-395 optimally (35-38). Another strength of this study is the inclusion of equal numbers of 396 men and women. Most studies in SA have either focused on women only or included 397 small samples of men (13-16; 23). Limitations of the study include the relatively small 398 sample size that precluded the validation of the threshold in a sub-sample of the 399 participants.

400

In conclusion, we show for the first time using prospective cohort data from SA that
African-specific thresholds derived for WC perform better than the IDF Europid WC
thresholds for predicting incident dysglycemia and type 2 diabetes in Black SA men
and women.

405

407 ACKNOWLEDGEMENTS

408

Author contributions: The authors confirm contribution to the paper as follows: study
conception and design: JHG and LKM; data collection: CK, MM, TC; data analysis:
JHG, KN, APK; interpretation of results: JHG, KN, APK, AEM, SAM, NJC, FK, TO,
LKM; draft manuscript preparation: JHG; All authors reviewed the results and
approved the final version of the manuscript.
Julia H. Goedecke is the guarantor and takes full responsibility for the contents of the
manuscript.

416

Funding: The study was jointly funded by the South African Medical Research Council (MRC) from South African National Department of Health, MRC UK (via the Newton Fund) and GSK Africa Non-Communicable Disease Open Lab (via a supporting Grant project Number: ES/N013891/1) and South African National Research Foundation (Grant no: UID:99108). TC is an International Training Fellow supported by the Wellcome Trust grant (214205/Z/18/Z).

Acknowledgements: We are grateful to the participants as well as the following DPHRU staff for their input during data collection and entry: Vukosi Mkansi, Sphume Thango, Mosadiapula Nakedi, Bonisiwe Mlambo, Melikhanya Soboyisi, Tshifhiwa Ratshikombo, and team.

423

424 **Conflict of interest**: The authors declare no conflicts of interest.

- 426 **Data availability**: Some or all datasets generated during and/or analyzed during the
- 427 current study are not publicly available but are available from the corresponding
- 428 author on reasonable request.
- 429

430 **References**

- 431 1. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S,
- 432 Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R, Committee IDFDA.
- 433 Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and
- 434 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition.
- 435 Diabetes Res Clin Pract 2019;157:107843
- 436 2. STATS-SA. Mortality and causes of death in South Africa, 2016: Findings from death
 437 notification. Statistics South Africa, 2018, p. 1-142
- 438 3. Okosun IS, Cooper RS, Rotimi CN, Osotimehin B, Forrester T. Association of waist 439 circumference with risk of hypertension and type 2 diabetes in Nigerians, Jamaicans, and
- 440 African-Americans. Diabetes Care 1998;21:1836-1842
- 4. Ross R, Neeland IJ, Yamashita S, Shai I, Seidell J, Magni P, Santos RD, Arsenault B,
 Cuevas A, Hu FB, Griffin BA, Zambon A, Barter P, Fruchart JC, Eckel RH, Matsuzawa Y,
 Despres JP. Waist circumference as a vital sign in clinical practice: a Consensus Statement
 from the IAS and ICCR Working Group on Visceral Obesity. Nat Rev Endocrinol
 2020;16:177-189
- 5. Pi-Sunyer FX. Obesity: criteria and classification. Proc Nutr Soc 2000;59:505-509
- 447 6. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, 448 James WP, Loria CM, Smith SC, Jr., International Diabetes Federation Task Force on E, 449 Prevention, Hational Heart L, Blood I, American Heart A, World Heart F, International 450 Atherosclerosis S, International Association for the Study of O. Harmonizing the metabolic 451 syndrome: a joint interim statement of the International Diabetes Federation Task Force on 452 Epidemiology and Prevention: National Heart, Lung, and Blood Institute: American Heart 453 Association; World Heart Federation; International Atherosclerosis Society; and International 454 Association for the Study of Obesity. Circulation 2009;120:1640-1645
- 455 7. Mtintsilana A, Micklesfield LK, Chorell E, Olsson T, Goedecke JH. Fat redistribution and
 456 accumulation of visceral adipose tissue predicts type 2 diabetes risk in middle-aged black
 457 South African women: a 13-year longitudinal study. Nutr Diabetes 2019;9:12
- 8. Chantler S, Dickie K, Micklesfield LK, Goedecke JH. Longitudinal Changes in Body Fat
 and Its Distribution in Relation to Cardiometabolic Risk in Black South African Women.
 Metab Syndr Relat Disord 2015;13:381-388
- 9. Goedecke JH, Levitt NS, Lambert EV, Utzschneider KM, Faulenbach MV, Dave JA, West
 S, Victor H, Evans J, Olsson T, Walker BR, Seckl JR, Kahn SE. Differential effects of
 abdominal adipose tissue distribution on insulin sensitivity in black and white South African
 women. Obesity (Silver Spring) 2009;17:1506-1512
- 10. Keswell D, Tootla M, Goedecke JH. Associations between body fat distribution, insulin
- resistance and dyslipidaemia in black and white South African women. Cardiovasc J Afr2016;27:177-183

468 11. Sumner AE, Micklesfield LK, Ricks M, Tambay AV, Avila NA, Thomas F, Lambert EV,

- Levitt NS, Evans J, Rotimi CN, Tulloch-Reid MK, Goedecke JH. Waist circumference, BMI,
 and visceral adipose tissue in white women and women of African descent. Obesity (Silver
- 471 Spring) 2011;19:671-674
- 472 12. World Health Organisation. Waist circumference and waist-hip ratio: report of a WHO473 expert Consulatation. Geneva, 2011
- 474 13. Matsha TE, Hassan MS, Hon GM, Soita DJ, Kengne AP, Erasmus RT. Derivation and
 475 validation of a waist circumference optimal cutoff for diagnosing metabolic syndrome in a
 476 South African mixed ancestry population. Int J Cardiol 2013;168:2954-2955
- 477 14. Crowther NJ, Norris SA. The current waist circumference cut point used for the diagnosis
 478 of metabolic syndrome in sub-Saharan African women is not appropriate. PLoS One
 479 2012;7:e48883
- 480 15. Ekoru K, Murphy GAV, Young EH, Delisle H, Jerome CS, Assah F, Longo-Mbenza B, 481 Nzambi JPD, On'Kin JBK, Buntix F, Muyer MC, Christensen DL, Wesseh CS, Sabir A, 482 Okafor C, Gezawa ID, Puepet F, Enang O, Raimi T, Ohwovoriole E, Oladapo OO, Bovet P, 483 Mollentze W, Unwin N, Gray WK, Walker R, Agoudavi K, Siziya S, Chifamba J, Njelekela M, 484 Fourie CM, Kruger S, Schutte AE, Walsh C, Gareta D, Kamali A, Seeley J, Norris SA, 485 Crowther NJ, Pillay D, Kaleebu P, Motala AA, Sandhu MS. Deriving an optimal threshold of 486 waist circumference for detecting cardiometabolic risk in sub-Saharan Africa. Int J Obes 487 (Lond) 2017;
- 488 16. Motala AA, Esterhuizen T, Pirie FJ, Omar MA. The prevalence of metabolic syndrome
 489 and determination of the optimal waist circumference cutoff points in a rural South african
 490 community. Diabetes Care 2011;34:1032-1037
- 491 17. Ali SA, Soo C, Agongo G, Alberts M, Amenga-Etego L, Boua RP, Choudhury A, 492 Crowther NJ, Depuur C, Gomez-Olive FX, Guiraud I, Haregu TN, Hazelhurst S, Kahn K, 493 Khayeka-Wandabwa C, Kyobutungi C, Lombard Z, Mashinya F, Micklesfield L, Mohamed 494 SF, Mukomana F, Nakanabo-Diallo S, Natama HM, Ngomi N, Nonterah EA, Norris SA, 495 Oduro AR, Some AM, Sorgho H, Tindana P, Tinto H, Tollman S, Twine R, Wade A, Sankoh 496 O, Ramsay M. Genomic and environmental risk factors for cardiometabolic diseases in 497 Africa: methods used for Phase 1 of the AWI-Gen population cross-sectional study. Glob 498 Health Action 2018;11:1507133
- 499 18. Ramsay M, Crowther N, Tambo E, Agongo G, Baloyi V, Dikotope S, Gomez-Olive X, Jaff 500 N, Sorgho H, Wagner R, Khayeka-Wandabwa C, Choudhury A, Hazelhurst S, Kahn K, 501 Lombard Z, Mukomana F, Soo C, Soodyall H, Wade A, Afolabi S, Agorinya I, Amenga-Etego 502 L, Ali SA, Bognini JD, Boua RP, Debpuur C, Diallo S, Fato E, Kazienga A, Konkobo SZ, 503 Kouraogo PM, Mashinya F, Micklesfield L, Nakanabo-Diallo S, Njamwea B, Nonterah E, 504 Ouedraogo S, Pillay V, Somande AM, Tindana P, Twine R, Alberts M, Kyobutungi C, Norris 505 SA, Oduro AR, Tinto H, Tollman S, Sankoh O. H3Africa AWI-Gen Collaborative Centre: a 506 resource to study the interplay between genomic and environmental risk factors for 507 cardiometabolic diseases in four sub-Saharan African countries. Glob Health Epidemiol 508 Genom 2016;1:e20
- 509 19. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the Concentration of Low510 Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge.
 511 Clinical Chemistry 1972;18:499-502
- 512 20. World Health Organization, International Diabetes F. Definition and diagnosis of diabetes
- 513 mellitus and intermediate hyperglycaemia : report of a WHO/IDF consultation. Geneva, 514 World Health Organization, 2006
- 515 21. Youden WJ. Index for rating diagnostic tests. Cancer 3:4

- 516 22. Bewick V, Cheek L, Ball J. Statistics review 13: receiver operating characteristic curves.
 517 Crit Care 2004;8:508-512
- 23. Peer N, Steyn K, Levitt N. Differential obesity indices identify the metabolic syndrome in
 Black men and women in Cape Town: the CRIBSA study. J Public Health (Oxf)
 2016;38:175-182
- 521 24. National Department of Health, ICF. South Africa Demographic and Health Survey 2016.
 522 Pretoria, National Department of Health NDoH ICF, 2019
- 523 25. Kabakambira JD, Baker RL, Jr., Briker SM, Courville AB, Mabundo LS, DuBose CW,
- 524 Chung ST, Eckel RH, Sumner AE. Do current guidelines for waist circumference apply to
- 525 black Africans? Prediction of insulin resistance by waist circumference among Africans living 526 in America BM I Clob Health 2018;3:e001057
- 526 in America. BMJ Glob Health 2018;3:e001057
- 527 26. Woudberg NJ, Goedecke JH, Blackhurst D, Frias M, James R, Opie LH, Lecour S.
- Association between ethnicity and obesity with high-density lipoprotein (HDL) function and
 subclass distribution. Lipids Health Dis 2016;15:92
- 27. Woudberg NJ, Lecour S, Goedecke JH. HDL Subclass Distribution Shifts with Increasing
 Central Adiposity. Journal of Obesity 2019;2019:1-6
- 28. Greiner R, Nyrienda M, Rodgers L, Asiki G, Banda L, Shields B, Hattersley A, Crampin
 A, Newton R, Jones A. Associations between low HDL, sex and cardiovascular risk markers
 are substantially different in sub-Saharan Africa and the UK: analysis of four population
 studies. BMJ Glob Health 2021;6
- 536 29. Knight MG, Goedecke JH, Ricks M, Evans J, Levitt NS, Tulloch-Reid MK, Sumner AE.
 537 The TG/HDL-C ratio does not predict insulin resistance in overweight women of African
 538 descent: a study of South African, African American and West African women. Ethn Dis
 539 2011;21:490-494
- Sumner AE, Cowie CC. Ethnic differences in the ability of triglyceride levels to identify
 insulin resistance. Atherosclerosis 2008;196:696-703
- 542 31. Sumner AE, Zhou J, Doumatey A, Imoisili OE, Amoah A, Acheampong J, Oli J, Johnson
- 543 T, Adebamowo C, Rotimi CN. Low HDL-Cholesterol with Normal Triglyceride Levels is the
- Most Common Lipid Pattern in West Africans and African Americans with Metabolic
 Syndrome: Implications for Cardiovascular Disease Prevention. CVD Prev Control
 2010:5:75-80
- 547 32. Sumner AE. Ethnic differences in triglyceride levels and high-density lipoprotein lead to
- underdiagnosis of the metabolic syndrome in black children and adults. J Pediatr
 2009;155:S7 e7-11
- 33. Yu SS, Ramsey NL, Castillo DC, Ricks M, Sumner AE. Triglyceride-based screening
 tests fail to recognize cardiometabolic disease in African immigrant and African-American
 men. Metab Syndr Relat Disord 2013;11:15-20
- 553 34. Evans J, Micklesfield L, Jennings C, Levitt NS, Lambert EV, Olsson T, Goedecke JH.
- 554 Diagnostic ability of obesity measures to identify metabolic risk factors in South African 555 women. Metab Syndr Relat Disord 2011;9:353-360
- 556 35. Kengne AP, Erasmus RT, Levitt NS, Matsha TE. Alternative indices of glucose
- homeostasis as biochemical diagnostic tests for abnormal glucose tolerance in an African
 setting. Prim Care Diabetes 2017;11:119-131
- 36. Wade AN, Crowther NJ, Abrahams-Gessel S, Berkman L, George JA, Gomez-Olive FX,
- 560 Manne-Goehler J, Salomon JA, Wagner RG, Gaziano TA, Tollman SM, Cappola AR.
- 561 Concordance between fasting plasma glucose and HbA1c in the diagnosis of diabetes in
- black South African adults: a cross-sectional study. BMJ Open 2021;11:e046060

- 37. Peer N, Steyn K, Lombard C, Lambert EV, Vythilingum B, Levitt NS. Rising diabetes
- prevalence among urban-dwelling black South Africans. PLoS One 2012;7:e43336
- 565 38. Motala AA, Esterhuizen T, Gouws E, Pirie FJ, Omar MA. Diabetes and other disorders of
- 566 glycemia in a rural South African community: prevalence and associated risk factors.
- 567 Diabetes Care 2008;31:1783-1788

569 **Table 1.** Characteristics of men and women at baseline

570

	Men (n=452)	Women (n=438)	P value	
Age (vears)	50 (45-55)	49 (45-54)	0.017	
Anthropometry		- ()		
BMI (kg/m2)	24.5 (20.8-29.1)	32.8 (28.5-37.3)	<0.001	
Waist circumference (cm)	88.1 (78.0-100.0)	98.1 (89.5-107.0)	<0.001	
Hip circumference (cm)	99.4 (91.2-106.1)	117.0 (108.5- 126.0)	<0.001	
WHR	0.90 (0.85-0.95)	0.84 (0.78-0.89)	<0.001	
WHtR	0.52 (0.46-0.58)	0.62 (0.56-0.67)	<0.001	
BMI categories				
Underweight (%(n))	10.0 (46)	0.5 (2)		
Normal weight (%(n))	42.6 (196)	11.0 (48)	-0.001	
Overweight (%(n))	26.5 (122)	21.9 (96)	~0.001	
Obese (%(n))	20.9 (96)	66.7 (292)]	
Biochemistry				
Fasting glucose (mmol/l)	5.1 (4.7-5.4)	4.8 (4.5-5.2)	<0.001	
Triglycerides (mmol/l)	0.9 (0.6-1.3)	1.0 (0.7-1.4)	<0.001	
Total cholesterol (mmol/l)	4.1 (3.4-4.8)	4.5 (3.8-5.2)	<0.001	
HDL-cholesterol (mmol/l)	1.2 (0.9-1.5)	1.2 (1.0-1.5)	0.063	
LDL-cholesterol (mmol/l)	2.5 (1.8-3.1)	2.7 (2.2-3.3)	<0.001	
Blood pressure				
Systolic (mmHg)	129.0 (117.0- 144.0)	128.5 (117.0- 141.5)	0.518	
Diastolic (mmHg)	88.8 (79.5-96.5)	87.5 (79.0-96.0)	0.357	
Metabolic syndrome (JIS)				
Elevated WC (%(n))	37.6 (170)	90.4 (396)	<0.001	
Elevated fasting glucose (%(n))	15.9 (72)	10.5 (46)	0.017	
Elevated triglycerides (%(n))	13.1 (59)	14.4 (63)	0.564	
Reduced HDL-cholesterol (%(n))	69.3 (313)	46.1 (202)	<0.001	
Elevated blood pressure (%(n))	61.3 (279)	59.6 (261)	0.514	
MetS (%(n))	30.3 (137)	35.4 (155)	0.107	

571

Values are median (25-75th percentile). WHR, waist-to-hip ratio; WHtR, waist-to-572 height ratio; MetS, metabolic syndrome, defined using the Joint Interim Statement 573 (JIS) (6) and defined as meeting any three of the following criteria: elevated waist 574 circumference (\geq 80 cm in women; \geq 94 cm in men); elevated blood glucose (\geq 5.6 575 576 mmol/l and/or using diabetes medication); elevated fasting triglycerides (≥1.7 577 mmol/L); reduced fasting HDL-cholesterol (<1.0 mmol/L in men, <1.3 mmol/L in 578 women); elevated blood pressure (≥135/85 mmHg and/or using antihypertension 579 medication). 580

581 **Table 2.** Performance measures of different waist circumference thresholds to

582 predict incident dysglycemia in Black African men and women

583

Reference	Cut-off (cm)	Sensitivity (95%Cl)	Specificity (95%CI)	PPV (95%Cl)	NPV (95%CI)	Youden index (95% Cl)
Men						
Youden	96.8	0.56 (0.44-0.68)	0.74 (0.69-0.78)	0.30 (0.23-0.39)	0.89 (0.85-0.92)	0.30 (0.13-0.46)
IDF (6)	94	0.59 (0.47-0.70)	0.68 (0.63-0.73)	0.27 (0.21-0.35)	0.89 (0.85-0.92)	0.27 (0.10-0.43)
Matsha et	90	0.66	0.59	0.25	0.89	0.25
al. (13)		(0.54-0.76)	(0.54-0.64)	(0.19-0.31)	(0.85-0.93)	(0.07-0.40)
Ekoru et	81	0.82	0.35	0.20	0.91	0.17
al. (15)		(0.72-0.90)	(0.30-0.40)	(0.16-0.26)	(0.84-0.95)	(0.01-0.30)
Motala et	86	0.68	0.48	0.21	0.88	0.17
al. (16)		(0.57-0.79)	(0.43-0.53)	(0.16-0.27)	(0.83-0.92)	(0.01-0.32)
Peer et al.	83.9	0.74	0.45	0.22	0.89	0.19
(23)		(0.62-0.84)	(0.40- 0.50)	(0.17-0.27)	(0.84-0.94)	(0.02-0.34)
MetS	96	0.44 (0.32-0.56)	0.77 (0.72-0.81)	0.28 (0.20-0.37)	0.87 (0.83-0.90)	0.21 (0.04-0.37)
Women						
Youden	91.8	0.86 (0.78-0.92)	0.37 (0.32-0.42)	0.30 (0.25-0.36)	0.89 (0.83-0.94)	0.23 (0.09-0.35)
IDF (6)	80	0.97 (0.92-0.99)	0.12 (0.09-0.16)	0.26 (0.22-0.31)	0.93 (0.81-0.99)	0.09 (0.01-0.16)
Matsha et	90	0.88	0.31	0.29	0.89	0.19
al. (13)		(0.80-0.94)	(0.26- 0.36)	(0.24-0.34)	(0.82-0.94)	(0.06-0.30)
Ekoru et	81	0.97	0.14	0.26	0.94	0.11
al. (15)		(0.92-0.99)	(0.10- 0.18)	(0.22-0.31)	(0.83-0.99)	(0.02-0.18)
Motala et	92	0.86	0.37	0.30	0.89	0.23
al. (16)		(0.78-0.92)	(0.32- 0.42)	(0.25-0.36)	(0.83-0.94)	(0.09-0.35)
Crowther	91.5	0.86	0.36	0.30	0.89	0.22
et al. (14)		(0.78-0.92)	(0.30- 0.41)	(0.25-0.35)	(0.82-0.94)	(0.08-0.33)
Peer et al.	94	0.76	0.43	0.30	0.85	0.19
(23)		(0.67-0.84)	(0.37-0.48)	(0.24-0.36)	(0.79-0.90)	(0.04-0.33)
MetS	96	0.38 (0.28-0.48)	0.80 (0.75-0.84)	0.37 (0.28-0.47)	0.80 (0.75-0.84)	0.17 (0.03-0.32)

584 Dysglycemia defined as impaired fasting glucose and/or impaired glucose tolerance 585 or type 2 diabetes; IDF, International Diabetes Federation; Sensitivity = TP/(TP+FN); 586 Specificity = TN/(TN+FP); PPV, positive predictive value = TP/(TP+FP); NPV, 587 negative predictive value = sensitivity/1-specificity; Youden's index = (sensitivity + 588 specificity)– 1, where TP, true positive; FP, false positive; TN, true negative; FN, 589 false negative; MetS, metabolic syndrome using a waist circumference threshold of 590 96 cm for men and women derived from this study.

592 **Table 3.** Performance measures of different waist circumference thresholds to

593 predict incident type 2 diabetes in Black African men and women

594

Reference	Cut- off (cm)	Sensitivity (95%Cl)	Specificity (95%Cl)	PPV (95%Cl)	NPV (95%Cl)	Youden index (95% Cl)
Men	<u> </u>	1				,
Youden	96.8	0.70 (0.46-0.88)	0.70 (0.65-0.74)	0.10 (0.05-0.16)	0.98 (0.96- 0.99)	0.40 (0.11- 0.62)
IDF (6)	94	0.70 (0.46-0.88)	0.64 (0.59-0.68)	0.08 (0.05-0.13)	0.98 (0.95- 0.99)	0.34 (0.05-0.57)
Matsha et al. (13)	90	0.75 (0.51-0.91)	0.55 (0.50-0.59)	0.07 (0.04-0.11)	0.98 (0.95- 0.99)	0.30 (0.01-0.51)
Ekoru et al. (15)	81	0.90 (0.68-0.99)	0.32 (0.27-0.36)	0.06 (0.03-0.09)	0.99 (0.95- 1.00)	0.22 (-0.04-0.35)
Motala et al. (16)	86	0.85 (0.62-0.97)	0.45 (0.40-0.50)	0.07 (0.04-0.10)	0.98 (0.96- 1.00)	0.30 (0.02-0.46)
Peer et al. (23)	83.9	0.85 (0.62-0.87)	0.41 (0.37-0.46)	0.06 (0.04-0.10)	0.98 (0.95- 1.00)	0.26 (-0.01-0.43)
MetS	96	0.45 (0.23-0.68)	0.72 (0.68-0.77)	0.07 (0.03-0.13)	0.97 (0.94-0.98)	0.17 (-0.09-0.45)
Women						
Youden	95.8	0.85 (0.72-0.94)	0.45 (0.40-0.50)	0.16 (0.11-0.21)	0.96 (0.92 0.98)	0.30 (0.12- 0.44)
IDF (6)	80	1.00 (0.92-1.00)	0.11 (0.08-0.14)	0.12 (0.09-0.15)	1.00 (0.92- 1.00)	0.11 (0.01-0.14)
Matsha et al. (13)	90	0.91 (0.80-0.98)	0.28 (0.23-0.32)	0.13 (0.10-0.17)	0.96 (0.91- 0.99)	0.19 (0.03-0.30)
Ekoru et al. (15)	81	1.00 (0.92-1.00)	0.12 (0.09-0.16)	0.12 (0.09-0.16)	1.00 (0.93- 1.00)	0.12 (0.02-0.16)
Motala et al. (16)	92	0.91 (0.80-0.98)	0.33 (0.29-0.38)	0.14 (0.10-0.19)	0.97 (0.93- 0.99)	0.24 (0.08-0.36)
Crowther et al. (14)	91.5	0.91 (0.80-0.98)	0.32 (0.28-0.37)	0.14 (0.10-0.18)	0.97 (0.92- 0.99)	0.24 (0.07-0.35)
Peer et al. (23)	94	0.87 (0.74-0.95)	0.40 (0.36-0.45)	0.15 (0.11-0.20)	0.96 (0.92-0.99)	0.28 (0.10-0.41)
MetS	96	0.49 (0.34-0.64)	0.76 (0.72-0.80)	0.20 (0.13-0.28)	0.93 (0.89-0.95)	0.25 (0.06-0.44)

IDF, International Diabetes Federation; Sensitivity = TP/(TP+FN); Specificity =
TN/(TN+FP); PPV, positive predictive value = TP/(TP+FP); NPV, negative predictive
value = sensitivity/1-specificity; Youden's index = (sensitivity + specificity)– 1, where
TP, true positive; FP, false positive; TN, true negative; FN, false negative; MetS,
metabolic syndrome using a waist circumference threshold of 96 cm for men and
women derived from this study.

601

603 FIGURE LEGENDS

604

- **Figure 1**. Consort Diagram for the Middle Aged Sowetan Cohort (MASC) waist
- 606 circumference study

607

- **Figure 2**. Receiver operating characteristics (ROC) curve of waist circumference to
- 609 predict incident dysglycemia (A) and type 2 diabetes (B) in Black African men and
- 610 women.

612 Figure 1.



618 **Figure 2**.





622 Supplementary Table S1. Comparative abilities of anthropometric measures at

baseline to predict incident dysglycemia and type 2 diabetes at follow-up in Black

624 African men and women

625

	AUC (95%CI)	P value vs. WC	P value vs.	P value vs. WHtR		
Mon (n=429)						
Waist	0.674 (0.600-0.748)	-				
circumference						
Waist-to-hip ratio	0.655 (0.584-0.726)	0.591	-			
Waist-to-height	0.681 (0.610-0.751)	0.425	0.395	-		
ratio	(, , , , , , , , , , , , , , , , , , ,					
Body mass index	0.653 (0.578-0.727)	0.073	0.938	0.017		
Women (n=420)						
Waist	0.620 (0.561-0.679)	-				
circumference						
Waist-to-hip ratio	0.625 (0.561-0.688)	0.866	-			
Waist-to-height	0.639 (0.579-0.699)	0.058	0.593	-		
ratio						
Body mass index	0.610 (0.550-0.670)	0.623	0.731	0.142		
Type 2 diabetes						
Men (n=451)						
Waist	0.728 (0.605-0.851)	-				
circumference						
Waist-to-hip ratio	0.710 (0.604-0.816)	0.587	-			
Waist-to-height	0.724 (0.603-0.845)	0.686	0.683	-		
ratio						
Body mass index	0.688 (0.556-0.821)	0.130	0.663	0.199		
Women (n=437)						
Waist	0.683 (0.607-0.758)	-				
circumference						
Waist-to-hip ratio	0.652 (0.570-0.735)	0.429	-			
Waist-to-height	0.693 (0.619-0.767)	0.351	0.289	-		
ratio						
Body mass index	0.691 (0.620-0.762)	0.721	0.473	0.944		

626 Values are area under the Receiver Operating Curve (AUC) and 95% confidence

627 interval (95%CI) and P-values for the difference in the AUC between adiposity

628 markers. WC, waist circumference; WHR, waist-to-hip ratio; WHtR, waist-to-height

629 ratio; BMI, body mass index.

630